Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 55 min ago
Peer-reviewedCC BY-NC-ND 4.0Nanomedicine

Real-world effectiveness of polymeric micellar paclitaxel versus albumin-bound paclitaxel in advanced esophageal squamous cell carcinoma: a retrospective study

  • Weiping He1
  • Lingli Chen2
  • Shuangjia Huang3
  • Pengwei Yan4
  • Xiaolin Liu5
5 affiliations
  1. 1Department of Pharmacy, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou, China
  2. 2Department of Critical Care Medicine, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
  3. 3Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
  4. 4Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
  5. 5Office of Ethics Committee, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
Read full textPDFDOICite

Abstract

Aims: To compare polymeric micellar paclitaxel (pm-PTX) and albumin-bound paclitaxel (nab-PTX) in first-line immunochemotherapy for advanced esophageal squamous cell carcinoma (ESCC).

Patients and method: We included 109 patients in efficacy and cost-effectiveness analyses (pm-PTX, n = 51; nab-PTX, n = 58) and 112 treatment initiators in safety analyses (pm-PTX, n = 52; nab-PTX, n = 60). Progression-free and overall survival (PFS and OS) were analyzed using Kaplan–Meier and overlap-weighted Cox models.

Results: Median PFS was 10.2 versus 16.7 months (pm-PTX vs nab-PTX, log-rank p = 0.148). After overlap weighting, no significant differences were observed in PFS (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.43–1.59; p = 0.574) or OS (HR, 1.32; 95% CI, 0.55–3.13; p = 0.536). OS analysis was immature. Response and disease control rates did not differ significantly. Any-grade gastrointestinal reactions, cough, and grade 3–4 anemia and neutropenia were more frequent with pm-PTX (40.4% vs. 10.0%, 11.5% vs. 0.0%, 7.7% vs. 0.0%, and 28.8% vs. 13.3%; p < 0.001, 0.009, 0.044, and 0.060, respectively). Taxane costs were higher with pm-PTX under Chinese pricing.

Conclusions: No statistically significant efficacy differences were observed. Both regimens showed manageable but distinct safety profiles; nab-PTX may be economically favorable.

Related

  1. Comparative effectiveness of neoadjuvant treatment strategies and predictors of pathological complete response in locally advanced esophageal squamous cell carcinoma: a real-world retrospective cohort study
    Xiaoli Yuan, Yuying Liang, Tianlin Han +8
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefPMC
  2. Chlorogenic Acid-Rich Fraction from Green Coffee Beans and Its Combination with Paclitaxel Attenuate Porphyromonas gingivalis LPS-Stimulated Esophageal Squamous Cell Carcinoma Related to the NF-ĸB and p38 Pathways
    Atita Panyathep, Khanittha Punturee, Teera Chewonarin
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  3. Clinical and CT body-composition model for major pathological response to neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin in esophageal squamous cell carcinoma
    Huiran Xu, Wei Zheng, Shumei Chen +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  4. Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Nanoparticle polymeric micellar paclitaxel (pm-Pac), platinum, and sintilimab as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer: a phase II study
    Xiaohua Wang, Li Wang, Shaorong Yu +13
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{he2026realworld,
  title = {{Real-world effectiveness of polymeric micellar paclitaxel versus albumin-bound paclitaxel in advanced esophageal squamous cell carcinoma: a retrospective study}},
  author = {Weiping He and Lingli Chen and Shuangjia Huang and Pengwei Yan and Xiaolin Liu},
  journal = {Nanomedicine},
  year = {2026},
  month = oct,
  doi = {10.1080/17435889.2026.2752930},
  url = {https://doi.org/10.1080/17435889.2026.2752930},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Real-world effectiveness of polymeric micellar paclitaxel versus albumin-bound paclitaxel in advanced esophageal squamous cell carcinoma: a retrospective study
AU  - Weiping He
AU  - Lingli Chen
AU  - Shuangjia Huang
AU  - Pengwei Yan
AU  - Xiaolin Liu
PY  - 2026
DA  - 2026/10/29
JO  - Nanomedicine
DO  - 10.1080/17435889.2026.2752930
UR  - https://doi.org/10.1080/17435889.2026.2752930
AB  - Aims: To compare polymeric micellar paclitaxel (pm-PTX) and albumin-bound paclitaxel (nab-PTX) in first-line immunochemotherapy for advanced esophageal squamous cell carcinoma (ESCC).  Patients and method: We included 109 patients in efficacy and cost-effectiveness analyses (pm-PTX, n = 51; nab-PTX, n = 58) and 112 treatment initiators in safety analyses (pm-PTX, n = 52; nab-PTX, n = 60). Progression-free and overall survival (PFS and OS) were analyzed using Kaplan–Meier and overlap-weighted Cox models.  Results: Median PFS was 10.2 versus 16.7 months (pm-PTX vs nab-PTX, log-rank p = 0.148). After overlap weighting, no significant differences were observed in PFS (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.43–1.59; p = 0.574) or OS (HR, 1.32; 95% CI, 0.55–3.13; p = 0.536). OS analysis was immature. Response and disease control rates did not differ significantly. Any-grade gastrointestinal reactions, cough, and grade 3–4 anemia and neutropenia were more frequent with pm-PTX (40.4% vs. 10.0%, 11.5% vs. 0.0%, 7.7% vs. 0.0%, and 28.8% vs. 13.3%; p < 0.001, 0.009, 0.044, and 0.060, respectively). Taxane costs were higher with pm-PTX under Chinese pricing.  Conclusions: No statistically significant efficacy differences were observed. Both regimens showed manageable but distinct safety profiles; nab-PTX may be economically favorable.
SN  - 1743-5889
SN  - 1748-6963
ER  -